The novel hydroxynaphthoquinone 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro.
The causal prophylactic activity of the novel hydroxynaphthoquinone, 566C80, was assessed against the exo-erythrocytic (EE) stages of Plasmodium berghei cultured in the human hepatoma cell line, HepG2. 566C80 was found to be highly active as an inhibitor of EE development and was more active than the established causal prophylactic pyrimethamine. A 566C80 concentration of 1.85 x 10(-9) M, added 3 h after sporozoite invasion, reduced the numbers of EE forms visible at 48 h by 50 degrees o, while the equivalent concentration of pyrimethamine was 1.95 x 10(-8) M.
Davies
C S
CS
Department of Pure and Applied Biology, Imperial College, London.
Pudney
M
M
Nicholas
J C
JC
Sinden
R E
RE
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D000981:Antiprotozoal Agents; D053626:Atovaquone; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008099:Liver / Q000469:parasitology*; D009024:Morphogenesis / Q000187:drug effects; D009285:Naphthoquinones / Q000494:pharmacology*; D010962:Plasmodium berghei / Q000187:drug effects* / Q000254:growth & development; D011739:Pyrimethamine / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000962:Antimalarials; D000981:Antiprotozoal Agents; D009285:Naphthoquinones; D053626:Atovaquone; D011739:Pyrimethamine